Does DIM Supplementation Change Estrogen Metabolism in Women on Estrogen Patches?

A 2025 clinical study tested DIM in postmenopausal women who were already using a transdermal estradiol patch^[7]. The researchers wanted to know if adding DIM would change estradiol levels or shift how the body metabolizes estrogen.

DIM comes from cruciferous vegetables like broccoli, cabbage, and kale. In the body, it is a breakdown product of indole-3-carbinol, a compound formed when these vegetables are chewed or digested.

The study found that DIM supplementation changed the pattern of estrogen metabolites in the women's blood or urine. Specifically, it appeared to favor certain estrogen breakdown pathways over others^[7].

However, DIM did not significantly lower the actual estradiol levels delivered by the patch^[7]. This is an important distinction.

The patch kept delivering the same amount of estradiol into the bloodstream, but the way the body processed that estradiol shifted.

Estradiol, the main estrogen used in hormone therapy, gets broken down by the liver into different metabolites. These include 2-hydroxyestrone, 4-hydroxyestrone, and 16alpha-hydroxyestrone.

Researchers have long been interested in the ratio between these metabolites.

Some early observational research suggested that a higher ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone might be linked to lower breast tissue proliferation, though this idea is still debated and not proven in large trials.

DIM is thought to push estrogen metabolism toward the 2-hydroxyestrone pathway. This is the theory behind why some women take DIM alongside hormone therapy.

The 2025 study offers direct evidence in women on patches, which is more useful than older studies that only looked at DIM alone or in women not using hormone therapy^[7].

Based on this study, the answer appears to be no^[7]. Estradiol levels stayed consistent with what the patch was designed to deliver.

This matters for women concerned that DIM might interfere with their hormone therapy dose. The data so far suggest DIM does not blunt the patch's effect on circulating estradiol.

What changes instead is the downstream metabolism, meaning how the liver processes the estradiol after it enters the bloodstream^[7].

If you are on transdermal estradiol therapy, this research suggests DIM would not reduce the amount of hormone reaching your bloodstream.

That is reassuring for anyone worried DIM could cancel out their prescribed dose.

At the same time, shifting estrogen metabolite ratios is not automatically good or bad. The clinical significance of these metabolite shifts is still not fully settled in the research.

Some other compounds studied in relation to estrogen and menopause include:

• Genistein and daidzein, soy isoflavones studied as phytoestrogens for menopause symptoms^[10]
• Isoflavones more broadly, studied for effects on bone mineral density in postmenopausal women^[15]
• Indole-3-carbinol, the dietary precursor that converts into DIM in the stomach

None of these have been tested together with DIM and estrogen patches in the same trial, so it is not clear how they would interact.

This is still an open question.

The 2025 study is one of the few to directly test DIM in women actively using a transdermal estradiol patch^[7], and it is a single study, not a large body of evidence.

Longer studies with more participants would help clarify whether the metabolite shifts seen with DIM have any real effect on breast tissue, uterine tissue, or overall safety over months or years.

Women using estrogen patches who are considering DIM should talk with the doctor managing their hormone therapy before adding it, since this research does not cover long term outcomes or interactions with other medications.